MCID: PLC011
MIFTS: 60

Pilocytic Astrocytoma malady

Categories: Rare diseases, Neuronal diseases, Cancer diseases

Aliases & Classifications for Pilocytic Astrocytoma

Aliases & Descriptions for Pilocytic Astrocytoma:

Name: Pilocytic Astrocytoma 12 50 56 29 52 14 69
Juvenile Pilocytic Astrocytoma 50 69
Grade I Astrocytic Tumor 12
Piloid Astrocytoma 12

Characteristics:

Orphanet epidemiological data:

56
pilocytic astrocytoma
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

Orphanet: 56  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:4851
MeSH 42 D001254
NCIt 47 C4047
Orphanet 56 ORPHA251612
ICD10 via Orphanet 34 C71.9
UMLS via Orphanet 70 C0334583
UMLS 69 C0334583

Summaries for Pilocytic Astrocytoma

NIH Rare Diseases : 50 pilocytic astrocytoma is an often benign, slow-growing tumor of the brain or spinal cord. the tumor may be in the form of a cyst and usually does not spread to nearby tissues. symptoms vary depending upon the size and location of the tumor. most symptoms result from increased pressure on the brain and include headaches, nausea, vomiting, balance problems, and vision abnormalities. the underlying cause of a pilocytic astrocytoma is unknown. it most commonly occurs in children and young adults, and in people with neurofibromatosis type 1 (nf1), li-fraumeni syndrome, and tuberous sclerosis. this type of tumor can often be cured with surgery. last updated: 8/9/2013

MalaCards based summary : Pilocytic Astrocytoma, also known as juvenile pilocytic astrocytoma, is related to juvenile pilocytic astrocytoma and pilocytic astrocytoma of cerebellum, and has symptoms including headache An important gene associated with Pilocytic Astrocytoma is KRAS (KRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are Apoptotic Pathways in Synovial Fibroblasts and ERK Signaling. The drugs Fentanyl and Donepezil have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and cerebellum, and related phenotypes are Decreased viability and behavior/neurological

Disease Ontology : 12 An astrocytoma that is characterized by cells that look like fibers when viewed under a microscope and is located in the brain.

Wikipedia : 71 Pilocytic astrocytoma or juvenile pilocytic astrocytoma or cystic cerebellar astrocytoma (and its... more...

Related Diseases for Pilocytic Astrocytoma

Diseases in the Pilocytic Astrocytoma family:

Juvenile Pilocytic Astrocytoma

Diseases related to Pilocytic Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 125)
id Related Disease Score Top Affiliating Genes
1 juvenile pilocytic astrocytoma 12.3
2 pilocytic astrocytoma of cerebellum 12.2
3 childhood pilocytic astrocytoma 12.2
4 astrocytoma 11.1
5 middle ear disease 10.4 GFAP IDH1 KIAA1549
6 biliary papillomatosis 10.4 BRAF GFAP KRAS
7 neurilemmoma 10.4 FGFR1 IDH1 NF1
8 pineal gland astrocytoma 10.4 BRAF IDH1 KIAA1549 NF1
9 paternal uniparental disomy of chromosome 1 10.4 GFAP IDH1 OLIG2
10 spinal cord astrocytoma 10.4 BRAF IDH1 KIAA1549 NF1
11 spondylarthropathy 10.3 BRAF CDKN2A HRAS
12 polg-related disorders 10.3 BRAF PTPN11 RAF1
13 amyloid tumor 10.3 BRAF GFAP IDH1 KIAA1549
14 postpoliomyelitis syndrome 10.3 CDKN2A HRAS KRAS
15 brain oligodendroglioma 10.3 GFAP IDH1 KIAA1549 OLIG2
16 cervical adenoid cystic carcinoma 10.3 GFAP NF1
17 flat ductal epithelial atypia 10.3 CDKN2A GFAP NF1 TIMP3
18 vascular myelopathy 10.3 CDKN2A NF1 SOX10
19 striated muscle rhabdoid tumor 10.3 CDKN2A HRAS KRAS
20 monckeberg arteriosclerosis 10.3 CDKN2A GFAP NF1 SOX10
21 ossifying fibromyxoid tumor 10.3 CDKN2A HRAS KRAS
22 aicardi-goutieres syndrome 10.3 CDKN2A HRAS KRAS
23 papillary tumor of the pineal region 10.3 GFAP IDH1
24 nephrolithiasis 10.3 HRAS NF1 PTPN11
25 pseudomonas stutzeri infections 10.3 BRAF KRAS PTPN11 RAF1
26 malignant skin fibrous histiocytoma 10.3 HRAS KRAS
27 adult oligodendroglioma 10.3 CDKN2A GFAP IDH1 OLIG2
28 arthus reaction 10.3 GFAP HRAS KRAS
29 rdh12-related leber congenital amaurosis 10.3 BRAF KRAS PTPN11 RAF1
30 glioblastoma 10.3
31 myxedema 10.3 CDKN2A HRAS KRAS
32 basophilic carcinoma 10.3 HRAS IDH1 KRAS
33 kidney clear cell sarcoma 10.3 HRAS KRAS NFIB
34 c-p angle neurinoma 10.3 GFAP NF1 SOX10
35 neurofibromatosis 10.3
36 hyperproinsulinemia 10.3 HRAS KRAS PTPN11
37 non-distal monosomy 10q 10.3 BRAF CDKN2A HRAS KRAS
38 advanced sleep phase syndrome 10.3 CDKN2A HRAS KRAS
39 brachial plexus neuropathy 10.3 HRAS KRAS RAF1
40 early myoclonic encephalopathy 10.3 FGFR1 GFAP IDH1
41 multifocal osteogenic sarcoma 10.3 CDKN2A HRAS KDR
42 medullary cystic kidney disease 1 10.3 HRAS KRAS NF1 PTPN11
43 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 3 10.3 BRAF CDKN2A HRAS SOX10
44 malignant pleural solitary fibrous tumor 10.2 CDKN2A GFAP HRAS IDH1 KRAS
45 benign shuddering attacks 10.2 CDKN2A HRAS KDR KRAS
46 chromosome 15q11-q13 duplication syndrome 10.2 BRAF HRAS NF1 PTPN11 RAF1
47 skin epithelioid hemangioma 10.2 BRAF HRAS NF1 PTPN11 RAF1
48 multinodular goiter 10.2 HRAS KDR KRAS
49 leopard syndrome 3 10.2 BRAF HRAS KRAS PTPN11 RAF1
50 central neurocytoma 10.2 GFAP NF1 SRGAP3

Graphical network of the top 20 diseases related to Pilocytic Astrocytoma:



Diseases related to Pilocytic Astrocytoma

Symptoms & Phenotypes for Pilocytic Astrocytoma

UMLS symptoms related to Pilocytic Astrocytoma:


headache

GenomeRNAi Phenotypes related to Pilocytic Astrocytoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 11.04 KRAS HRAS BRAF
2 Decreased viability GR00106-A-0 11.04 ERBB3 KRAS
3 Decreased viability GR00221-A-1 11.04 KRAS RAF1 FGFR1 HRAS KDR NF1
4 Decreased viability GR00221-A-2 11.04 KRAS RAF1 HRAS NTRK2 FGFR1 KDR
5 Decreased viability GR00221-A-3 11.04 HRAS KDR CDKN2A
6 Decreased viability GR00221-A-4 11.04 KDR NF1 NTRK2 ERBB3 CDKN2A BRAF
7 Decreased viability GR00231-A 11.04 RAF1
8 Decreased viability GR00301-A 11.04 ERBB3 KRAS RAF1 BRAF
9 Decreased viability GR00342-S-2 11.04 ERBB3
10 Decreased viability GR00342-S-3 11.04 ERBB3
11 Decreased viability GR00381-A-1 11.04 KRAS BRAF
12 Decreased viability in esophageal squamous lineage GR00235-A 10 BRAF CDKN2A GFAP HRAS IDH1 KIAA1549
13 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.97 FGFR1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.97 BRAF
15 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.97 PTPN11
16 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.97 PTPN11
17 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.97 FGFR1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.97 FGFR1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.97 IDH1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.97 SRGAP3
21 Increased shRNA abundance (Z-score > 2) GR00366-A-136 9.97 IDH1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-138 9.97 IDH1 PTPN11
23 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.97 IDH1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.97 PTPN11 BRAF
25 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.97 SRGAP3
26 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.97 BRAF
27 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.97 FGFR1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-172 9.97 IDH1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.97 BRAF
30 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.97 PTPN11
31 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.97 FGFR1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.97 PTPN11
33 Increased shRNA abundance (Z-score > 2) GR00366-A-194 9.97 BRAF
34 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.97 SRGAP3
35 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.97 BRAF
36 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.97 SRGAP3
37 Increased shRNA abundance (Z-score > 2) GR00366-A-31 9.97 BRAF
38 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.97 BRAF
39 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.97 SRGAP3
40 Increased shRNA abundance (Z-score > 2) GR00366-A-37 9.97 PTPN11
41 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.97 IDH1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.97 SRGAP3 FGFR1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.97 FGFR1 IDH1 PTPN11 BRAF SRGAP3
44 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.97 FGFR1
45 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.97 PTPN11
46 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.97 FGFR1
47 Increased shRNA abundance (Z-score > 2) GR00366-A-78 9.97 PTPN11
48 Increased shRNA abundance (Z-score > 2) GR00366-A-82 9.97 SRGAP3
49 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.97 FGFR1
50 Decreased cell migration GR00055-A-1 9.91 BRAF HRAS KDR KRAS NF1 SRGAP3
51 Decreased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 9.88 BRAF ERBB3 FGFR1 KDR NTRK2 RAF1
52 Decreased substrate adherent cell growth GR00193-A-3 9.67 BRAF
53 Decreased substrate adherent cell growth GR00193-A-4 9.67 BRAF FGFR1 KDR
54 Increased cell migration GR00055-A-3 9.63 BRAF HRAS KDR KRAS NF1 SRGAP3
55 Increased senescence-associated beta-galactosidase protein expression after pRB stimulation GR00230-A-2 9.13 ERBB3 NTRK2 RAF1

MGI Mouse Phenotypes related to Pilocytic Astrocytoma:

44 (show all 23)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.54 BRAF CDKN2A ERBB3 SOX10 SRGAP3 TIMP3
2 growth/size/body region MP:0005378 10.51 RAF1 SOX10 TIMP3 BRAF CDKN2A ERBB3
3 homeostasis/metabolism MP:0005376 10.49 KRAS NF1 NFIB NTRK2 PBX3 PTPN11
4 cellular MP:0005384 10.47 RAF1 SOX10 TIMP3 BRAF CDKN2A ERBB3
5 mortality/aging MP:0010768 10.45 HRAS IDH1 KDR KRAS NF1 NFIB
6 cardiovascular system MP:0005385 10.42 BRAF CDKN2A ERBB3 FGFR1 GFAP HRAS
7 endocrine/exocrine gland MP:0005379 10.38 BRAF CDKN2A ERBB3 FGFR1 HRAS KRAS
8 nervous system MP:0003631 10.33 BRAF CDKN2A ERBB3 FGFR1 GFAP HRAS
9 digestive/alimentary MP:0005381 10.32 BRAF CDKN2A ERBB3 FGFR1 GFAP KRAS
10 integument MP:0010771 10.32 BRAF CDKN2A ERBB3 FGFR1 HRAS KDR
11 immune system MP:0005387 10.3 PTPN11 RAF1 TIMP3 BRAF CDKN2A ERBB3
12 embryo MP:0005380 10.27 BRAF CDKN2A ERBB3 FGFR1 KDR KRAS
13 craniofacial MP:0005382 10.24 BRAF FGFR1 HRAS KRAS NF1 NFIB
14 muscle MP:0005369 10.23 FGFR1 GFAP KDR KRAS NF1 OLIG2
15 liver/biliary system MP:0005370 10.15 BRAF CDKN2A KDR KRAS NF1 NTRK2
16 neoplasm MP:0002006 10.13 BRAF CDKN2A ERBB3 HRAS KRAS NF1
17 normal MP:0002873 10.1 KRAS NF1 NTRK2 PTPN11 RAF1 BRAF
18 hearing/vestibular/ear MP:0005377 10.09 KRAS NF1 NTRK2 PTPN11 RAF1 BRAF
19 respiratory system MP:0005388 10.06 BRAF CDKN2A ERBB3 HRAS IDH1 KDR
20 no phenotypic analysis MP:0003012 9.97 CDKN2A FGFR1 HRAS KDR KRAS OLIG2
21 pigmentation MP:0001186 9.86 BRAF CDKN2A ERBB3 KRAS NF1 PTPN11
22 skeleton MP:0005390 9.77 NF1 NTRK2 OLIG2 PBX3 PTPN11 BRAF
23 vision/eye MP:0005391 9.44 NFIB NTRK2 OLIG2 PTPN11 RAF1 TIMP3

Drugs & Therapeutics for Pilocytic Astrocytoma

Drugs for Pilocytic Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 162)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
3
Vincristine Approved, Investigational Phase 2, Phase 3,Phase 1 2068-78-2, 57-22-7 5978
4
Lomustine Approved Phase 2, Phase 3 13010-47-4 3950
5
Procarbazine Approved Phase 2, Phase 3 671-16-9 4915
6
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
7
Cyproheptadine Approved Phase 3 129-03-3 2913
8
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
9
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
10 Alkylating Agents Phase 2, Phase 3,Phase 1
11 Antineoplastic Agents, Alkylating Phase 2, Phase 3,Phase 1
12 Dermatologic Agents Phase 3,Phase 2,Phase 1
13 Adjuvants, Anesthesia Phase 3
14 Analgesics Phase 3
15 Analgesics, Opioid Phase 3
16 Anesthetics Phase 3
17 Anesthetics, General Phase 3
18 Anesthetics, Intravenous Phase 3
19 Central Nervous System Depressants Phase 3
20 Liver Extracts Phase 3,Phase 2,Phase 1
21 Narcotics Phase 3
22 pancreatic polypeptide Phase 3,Phase 1
23 Peripheral Nervous System Agents Phase 3
24 Cholinergic Agents Phase 3,Phase 2
25 Cholinesterase Inhibitors Phase 3,Phase 2
26 Neurotransmitter Agents Phase 3,Phase 2
27 Nootropic Agents Phase 3,Phase 2
28 Antimitotic Agents Phase 2, Phase 3,Phase 1
29 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 1
30 Gastrointestinal Agents Phase 3,Phase 1
31 Central Nervous System Stimulants Phase 3,Phase 2
32 Dopamine Agents Phase 3
33 Anti-Allergic Agents Phase 3
34 Antipruritics Phase 3
35 Histamine Antagonists Phase 3
36 Histamine H1 Antagonists Phase 3
37
Histamine Phosphate Phase 3 51-74-1 65513
38
Serotonin Phase 3 50-67-9 5202
39 Serotonin Agents Phase 3
40 Serotonin Antagonists Phase 3
41 Dexmethylphenidate Hydrochloride Phase 3
42 Dopamine Uptake Inhibitors Phase 3
43 Neurotransmitter Uptake Inhibitors Phase 3
44 Cola Nutraceutical Phase 3,Phase 1
45
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
46
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
47
Trioxsalen Approved Phase 2,Phase 1 3902-71-4 5585
48
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177
49
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
50
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030 46835353

Interventional clinical trials:

(show top 50) (show all 68)
id Name Status NCT ID Phase
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
2 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3
3 Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma Active, not recruiting NCT00003375 Phase 2, Phase 3
4 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
5 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3
6 Antineoplaston Therapy in Treating Patients With Low-Grade Astrocytoma Unknown status NCT00003471 Phase 2
7 Temozolomide in Treating Patients With Low-Grade Glioma Completed NCT00313729 Phase 2
8 Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma Completed NCT00112736 Phase 1, Phase 2
9 Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma Completed NCT00003467 Phase 2
10 Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors Completed NCT00025675 Phase 2
11 Temozolomide in Treating Patients With Progressive Low-Grade Glioma Completed NCT00003466 Phase 2
12 Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas Completed NCT00274755 Phase 2
13 Imatinib Mesylate in Treating Patients With Gliomas Completed NCT00039364 Phase 2
14 Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Completed NCT00498927 Phase 2
15 Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors Completed NCT00541138 Phase 2
16 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2
17 Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors Completed NCT01032200 Phase 2
18 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers Completed NCT00002752 Phase 1, Phase 2
19 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors Completed NCT00003461 Phase 1, Phase 2
20 Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma Completed NCT00010049 Phase 1, Phase 2
21 Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor Completed NCT00070161 Phase 2
22 Antineoplaston Therapy in Treating Children With Brain Tumors Completed NCT00003458 Phase 2
23 Antineoplaston Therapy in Treating Patients With Brain Tumors Completed NCT00003457 Phase 2
24 Phase II Pegylated Interferon Recruiting NCT02343224 Phase 2
25 A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas Recruiting NCT01837862 Phase 1, Phase 2
26 Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma Recruiting NCT01089101 Phase 1, Phase 2
27 Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas Recruiting NCT01966809 Phase 2
28 Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma Active, not recruiting NCT01553149 Phase 2
29 Bevacizumab in Recurrent Grade II and III Glioma Active, not recruiting NCT01164189 Phase 2
30 Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Active, not recruiting NCT00553150 Phase 1, Phase 2
31 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
32 Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Active, not recruiting NCT00939770 Phase 1, Phase 2
33 Functional Magnetic Resonance Imaging and 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Treating Patients With Newly Diagnosed Brain Tumors Withdrawn NCT00005083 Phase 2
34 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1
35 Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas Unknown status NCT00083096 Phase 1
36 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1
37 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1
38 Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers Completed NCT00498979 Phase 1
39 Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment Completed NCT00544284 Phase 1
40 Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma Completed NCT00509431 Phase 1
41 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1
42 BCX-1777 in Treating Patients With Refractory Cancer Completed NCT00073944 Phase 1
43 Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer Completed NCT00003022 Phase 1
44 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1
45 Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas Completed NCT00019019 Phase 1
46 Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors Completed NCT00008086 Phase 1
47 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
48 Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors Completed NCT00003484 Phase 1
49 Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma Completed NCT01273090 Phase 1
50 Cognitive Biomarkers in Pediatric Brain Tumor Patients Recruiting NCT02914067 Phase 1

Search NIH Clinical Center for Pilocytic Astrocytoma

Genetic Tests for Pilocytic Astrocytoma

Genetic tests related to Pilocytic Astrocytoma:

id Genetic test Affiliating Genes
1 Pilocytic Astrocytoma 29

Anatomical Context for Pilocytic Astrocytoma

MalaCards organs/tissues related to Pilocytic Astrocytoma:

39
Brain, Spinal Cord, Cerebellum, Pineal, Endothelial, Tongue, Temporal Lobe

The Foundational Model of Anatomy Ontology organs/tissues related to Pilocytic Astrocytoma:

18
The Brain

Publications for Pilocytic Astrocytoma

Articles related to Pilocytic Astrocytoma:

(show top 50) (show all 386)
id Title Authors Year
1
Longitudinal mutational analysis of a cerebellar pilocytic astrocytoma recurring as a ganglioglioma. ( 27718322 )
2017
2
Hydrocephalus associated with spinal intramedullary pilocytic astrocytoma. ( 28484535 )
2017
3
Spontaneous aneurysmal subarachnoid haemorrhage in a child with multiply recurrent posterior fossa juvenile pilocytic astrocytoma. ( 27927709 )
2016
4
Spontaneous complete regression of hypothalamic pilocytic astrocytoma after partial resection in a child, complicated with Stevens-Johnson syndrome: a case report and literature review. ( 26662551 )
2016
5
Hypothalamic-Optochiasmatic Pilocytic Astrocytoma Associated with Occipital and Sacral Spinal Cavernomas: A Mere Coincidence or a True Association? ( 27004758 )
2016
6
Infratentorial ganglioglioma mimicking pilocytic astrocytoma. ( 27936528 )
2016
7
Report of effective trametinib therapy in 2 children with progressive hypothalamic optic pathway pilocytic astrocytoma: documentation of volumetric response. ( 28009226 )
2016
8
Cranial pilocytic astrocytoma with spinal drop metastasis in an adult: case report and literature review. ( 27535634 )
2016
9
Retraction: Screening genes crucial for pediatric pilocytic astrocytoma using weighted gene coexpression network analysis combined with methylation data analysis. ( 26685762 )
2016
10
Low rates of recurrence and slow progression of pediatric pilocytic astrocytoma after gross-total resection: justification for reducing surveillance imaging. ( 26722760 )
2016
11
MR imaging of brain pilocytic astrocytoma: beyond the stereotype of benign astrocytoma. ( 27757570 )
2016
12
Coexistent dysembryoplastic neuroepithelial tumour and pilocytic astrocytoma. ( 27695565 )
2016
13
Massive Calcified Cerebellar Pilocytic Astrocytoma with Rapid Recurrence : A Rare Case. ( 27651876 )
2016
14
Postoperative surveillance of pediatric cerebellar pilocytic astrocytoma. ( 27502785 )
2016
15
Suprasellar pilocytic astrocytoma in an adult with hemorrhage and leptomeningeal dissemination: case report and review of literature. ( 27920871 )
2016
16
Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing. ( 28002790 )
2016
17
Genetic alterations related to BRAF-FGFR genes and dysregulated MAPK/ERK/mTOR signaling in adult pilocytic astrocytoma. ( 27608415 )
2016
18
Cervical spinal pilocytic astrocytoma. ( 26916806 )
2016
19
Pilocytic astrocytoma. ( 27033282 )
2016
20
Leptomeningeal dissemination and vertebral bone involvement in a child with pilocytic astrocytoma. ( 27859985 )
2016
21
Pilocytic Astrocytoma of fornix mimicking a colloid cyst: report of two cases and review of the literature. ( 28024978 )
2016
22
Tanycytic ependymoma vs pilocytic astrocytoma? Pitfalls in diagnosis. ( 27773093 )
2016
23
miR-15a and miR-24-1 as putative prognostic microRNA signatures for pediatric pilocytic astrocytomas and ependymomas. ( 26813564 )
2016
24
Malignant progression of a histone H3.3 K27M-mutated spinal pilocytic astrocytoma in an adult. ( 27900936 )
2016
25
Adult anaplastic pilocytic astrocytoma - a diagnostic challenge? A case series and literature review. ( 27341279 )
2016
26
Using urinary bFGF and TIMP3 levels to predict the presence of juvenile pilocytic astrocytoma and establish a distinct biomarker signature. ( 27314542 )
2016
27
A new NFIA:RAF1 fusion activating the MAPK pathway in pilocytic astrocytoma. ( 27810072 )
2016
28
A rare case of infantile cerebellar pilocytic astrocytoma and thrombocytopenia presenting with intratumoral hemorrhage. ( 27857799 )
2016
29
Heterogeneity of histopathological presentation of pilocytic astrocytoma - diagnostic pitfalls. A review. ( 27764513 )
2016
30
Primary Orbital Cystic Pilocytic Astrocytoma. ( 27843910 )
2016
31
A case of pilocytic astrocytoma requiring tumor resection during pregnancy. ( 27073664 )
2016
32
Diffuse Spinal Leptomeningeal Spread of a Pilocytic Astrocytoma in a 3-year-old Child. ( 27162602 )
2016
33
Whole Chromosome 7 Gain Predicts Higher Risk of Recurrence in Pediatric Pilocytic Astrocytomas Independently From KIAA1549-BRAF Fusion Status. ( 26945035 )
2016
34
MRS of pilocytic astrocytoma: The peak at 2a88ppm may not be NAA. ( 27529659 )
2016
35
Pilocytic astrocytoma and glioneuronal tumor with histone H3 K27M mutation. ( 27519587 )
2016
36
Pineal region pilocytic astrocytoma; an unusual site with variable radiological, clinical, and histological features: A report of two cases. ( 27365971 )
2016
37
TP53 codon 72 polymorphism may predict early tumour progression in paediatric pilocytic astrocytoma. ( 27374106 )
2016
38
A Novel Syndrome of Generalized Lipodystrophy Associated With Pilocytic Astrocytoma. ( 26252356 )
2015
39
Sporadic Retinoblastoma and Pilocytic Astrocytoma: A Rare Association of Two Tumors. ( 26173175 )
2015
40
Contralateral Anterior Inter-hemispheric Transparaterminal Gyrus Approach for Thalamopeduncular Pilocytic Astrocytoma in an Adult: Technical Report. ( 26409092 )
2015
41
Model-Based Evaluation of Spontaneous Tumor Regression in Pilocytic Astrocytoma. ( 26658166 )
2015
42
IDH1 R132H mutation in a pilocytic astrocytoma: a case report. ( 26617931 )
2015
43
Diffuse leptomeningeal spread of supratentorial recurrent pilocytic astrocytoma in a child. ( 26962359 )
2015
44
Long survival in a child with a mutated K27M-H3.3 pilocytic astrocytoma. ( 25909089 )
2015
45
Adult recurrent pilocytic astrocytoma: Clinical, histopathological and molecular study. ( 26597605 )
2015
46
Pilocytic astrocytoma: pathology, molecular mechanisms and markers. ( 25792358 )
2015
47
Intramedullary pilocytic astrocytoma. ( 26133253 )
2015
48
Pilocytic astrocytoma presenting as an orbital encephalocele: a case report. ( 26034483 )
2015
49
Pilocytic astrocytoma at the medulla oblongata dorsal surface presenting as intractable hiccups. ( 25443583 )
2015
50
Expression of Methylthioadenosine Phosphorylase (MTAP) in Pilocytic Astrocytomas. ( 26088413 )
2015

Variations for Pilocytic Astrocytoma

ClinVar genetic disease variations for Pilocytic Astrocytoma:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 KRAS NM_033360.3(KRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic rs121913535 GRCh37 Chromosome 12, 25398282: 25398282

Copy number variations for Pilocytic Astrocytoma from CNVD:

7 (show all 22)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 38161 10 1 3000000 Gain DIP2C Pilocytic astrocytoma
2 40599 10 130600000 135534747 Loss DRD1IP Pilocytic astrocytoma
3 64537 12 129300000 133851895 Loss BCL7A Pilocytic astrocytoma
4 84233 14 24600000 33300000 Loss FOXG1B Pilocytic astrocytoma
5 97079 15 98500000 102531392 Loss LASS3 Pilocytic astrocytoma
6 112680 17 40811265 40819024 Loss TUBG2 Pilocytic astrocytoma
7 112684 17 40834631 40852011 Loss CNTNAP1 Pilocytic astrocytoma
8 220399 7 138200000 143100000 Amplification Pilocytic astrocytoma
9 227901 7 72200000 77500000 Loss BCL7B Pilocytic astrocytoma
10 230764 8 1 2200000 Loss Pilocytic astrocytoma
11 234563 8 136400000 146364022 Gain COL22A1 Pilocytic astrocytoma
12 234873 8 139900000 146364022 Gain CYHR1 Pilocytic astrocytoma
13 234878 8 139900000 146364022 Gain FOXH1 Pilocytic astrocytoma
14 234881 8 139900000 146364022 Gain GPT Pilocytic astrocytoma
15 234884 8 139900000 146364022 Gain KIFC2 Pilocytic astrocytoma
16 234886 8 139900000 146364022 Gain LRRC14 Pilocytic astrocytoma
17 234888 8 139900000 146364022 Gain LRRC24 Pilocytic astrocytoma
18 234890 8 139900000 146364022 Gain MFSD3 Pilocytic astrocytoma
19 234893 8 139900000 146364022 Gain PPP1R16A Pilocytic astrocytoma
20 234897 8 139900000 146364022 Gain RECQL4 Pilocytic astrocytoma
21 244900 9 1 2200000 Loss ANKRD15 Pilocytic astrocytoma
22 256191 9 9000000 28000000 Loss SH3GL2 Pilocytic astrocytoma

Expression for Pilocytic Astrocytoma

Search GEO for disease gene expression data for Pilocytic Astrocytoma.

Pathways for Pilocytic Astrocytoma

Pathways related to Pilocytic Astrocytoma according to GeneCards Suite gene sharing:

(show top 50) (show all 106)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.94 BRAF CDKN2A FGFR1 HRAS KDR KRAS
2
Show member pathways
13.87 BRAF CDKN2A ERBB3 FGFR1 GFAP HRAS
3
Show member pathways
13.82 BRAF CDKN2A ERBB3 FGFR1 HRAS KDR
4
Show member pathways
13.81 BRAF ERBB3 FGFR1 HRAS IDH1 KIAA1549
5
Show member pathways
13.64 BRAF ERBB3 FGFR1 HRAS KDR KRAS
6
Show member pathways
13.6 BRAF ERBB3 FGFR1 HRAS KDR KRAS
7
Show member pathways
13.55 BRAF ERBB3 FGFR1 HRAS KDR KRAS
8
Show member pathways
13.5 ERBB3 FGFR1 HRAS KDR KRAS NTRK2
9
Show member pathways
13.44 BRAF ERBB3 FGFR1 HRAS KRAS NF1
10
Show member pathways
13.4 ERBB3 FGFR1 HRAS KDR KRAS NTRK2
11
Show member pathways
13.38 FGFR1 HRAS KDR KRAS NTRK2 PTPN11
12
Show member pathways
13.32 BRAF ERBB3 FGFR1 HRAS KDR KRAS
13
Show member pathways
13.12 FGFR1 HRAS KDR KRAS NTRK2 RAF1
14
Show member pathways
13.1 BRAF FGFR1 HRAS KDR KRAS NTRK2
15
Show member pathways
13.07 ERBB3 FGFR1 HRAS KDR NTRK2 RAF1
16
Show member pathways
13.02 BRAF CDKN2A ERBB3 FGFR1 HRAS KDR
17
Show member pathways
12.99 BRAF ERBB3 HRAS KRAS PTPN11 RAF1
18
Show member pathways
12.93 BRAF ERBB3 FGFR1 HRAS KRAS NTRK2
19
Show member pathways
12.87 BRAF HRAS KRAS NTRK2 RAF1
20
Show member pathways
12.86 BRAF HRAS KRAS PTPN11 RAF1
21
Show member pathways
12.84 BRAF ERBB3 HRAS KRAS NTRK2 PTPN11
22
Show member pathways
12.81 ERBB3 FGFR1 HRAS KRAS PTPN11
23 12.75 BRAF CDKN2A FGFR1 HRAS KRAS RAF1
24 12.75 BRAF FGFR1 HRAS KRAS NF1 NTRK2
25 12.72 BRAF FGFR1 HRAS KRAS RAF1
26
Show member pathways
12.7 BRAF FGFR1 HRAS KDR KRAS NF1
27 12.68 FGFR1 HRAS KDR KRAS RAF1
28
Show member pathways
12.68 HRAS KDR KRAS PTPN11 RAF1
29
Show member pathways
12.67 BRAF FGFR1 HRAS KRAS PTPN11
30
Show member pathways
12.65 BRAF ERBB3 HRAS KRAS RAF1
31
Show member pathways
12.6 BRAF HRAS KRAS PTPN11 RAF1
32 12.58 CDKN2A ERBB3 HRAS KRAS RAF1 TIMP3
33
Show member pathways
12.54 BRAF ERBB3 FGFR1 HRAS KDR KRAS
34
Show member pathways
12.53 FGFR1 HRAS KRAS PTPN11 RAF1
35
Show member pathways
12.49 HRAS KRAS PTPN11 RAF1
36
Show member pathways
12.49 ERBB3 FGFR1 HRAS KDR KRAS NTRK2
37
Show member pathways
12.47 BRAF HRAS KRAS RAF1
38
Show member pathways
12.47 HRAS KRAS PTPN11 RAF1
39
Show member pathways
12.46 BRAF HRAS KRAS PTPN11 RAF1
40
Show member pathways
12.44 HRAS KDR KRAS RAF1
41
Show member pathways
12.43 BRAF HRAS KRAS RAF1
42
Show member pathways
12.41 BRAF HRAS KRAS RAF1
43
Show member pathways
12.4 HRAS KRAS PTPN11 RAF1
44
Show member pathways
12.39 BRAF ERBB3 HRAS KRAS RAF1
45
Show member pathways
12.37 BRAF HRAS KRAS NF1 RAF1
46
Show member pathways
12.34 BRAF FGFR1 HRAS KRAS PTPN11
47
Show member pathways
12.34 BRAF HRAS KDR KRAS NF1 PTPN11
48
Show member pathways
12.3 GFAP HRAS PTPN11 RAF1
49 12.3 HRAS KRAS PTPN11 RAF1 SRGAP3
50
Show member pathways
12.3 BRAF HRAS KRAS PTPN11 RAF1 TIMP3

GO Terms for Pilocytic Astrocytoma

Cellular components related to Pilocytic Astrocytoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.47 BRAF CDKN2A FGFR1 GFAP HRAS IDH1

Biological processes related to Pilocytic Astrocytoma according to GeneCards Suite gene sharing:

(show all 29)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.95 BRAF ERBB3 HRAS KRAS NTRK2
2 heart development GO:0007507 9.93 ERBB3 NF1 PTPN11 RAF1
3 regulation of cell proliferation GO:0042127 9.92 BRAF ERBB3 FGFR1 NF1
4 peptidyl-tyrosine phosphorylation GO:0018108 9.87 ERBB3 FGFR1 KDR NTRK2
5 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.81 ERBB3 FGFR1 PTPN11
6 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.79 BRAF NTRK2 RAF1
7 negative regulation of signal transduction GO:0009968 9.78 BRAF ERBB3 RAF1
8 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.77 BRAF HRAS KDR PTPN11 RAF1
9 positive regulation of MAP kinase activity GO:0043406 9.76 FGFR1 HRAS KRAS
10 epidermal growth factor receptor signaling pathway GO:0007173 9.75 HRAS KRAS PTPN11
11 positive regulation of MAPK cascade GO:0043410 9.73 FGFR1 HRAS KDR NTRK2
12 visual learning GO:0008542 9.71 BRAF KRAS NF1
13 ERBB2 signaling pathway GO:0038128 9.7 ERBB3 HRAS KRAS
14 oligodendrocyte differentiation GO:0048709 9.69 NTRK2 OLIG2 SOX10
15 peripheral nervous system development GO:0007422 9.65 ERBB3 NF1 SOX10
16 regulation of synaptic transmission, GABAergic GO:0032228 9.64 KRAS NF1
17 Ras protein signal transduction GO:0007265 9.62 CDKN2A HRAS KRAS NF1
18 response to isolation stress GO:0035900 9.61 HRAS KRAS
19 positive regulation of cellular senescence GO:2000774 9.59 CDKN2A KRAS
20 regulation of long-term neuronal synaptic plasticity GO:0048169 9.58 HRAS KRAS NF1
21 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.56 ERBB3 FGFR1 KDR NTRK2
22 positive regulation of protein phosphorylation GO:0001934 9.55 HRAS KDR KRAS NTRK2 RAF1
23 forebrain astrocyte development GO:0021897 9.49 KRAS NF1
24 negative regulation of neuron apoptotic process GO:0043524 9.35 BRAF ERBB3 HRAS KRAS NTRK2
25 MAPK cascade GO:0000165 9.17 BRAF ERBB3 FGFR1 HRAS KRAS NF1
26 positive regulation of cell proliferation GO:0008284 10.04 FGFR1 HRAS KDR KRAS NTRK2
27 protein phosphorylation GO:0006468 10.03 BRAF ERBB3 FGFR1 KDR NTRK2 RAF1
28 negative regulation of cell proliferation GO:0008285 10 CDKN2A HRAS NF1 NFIB RAF1
29 phosphorylation GO:0016310 10 BRAF CDKN2A ERBB3 FGFR1 KDR NTRK2

Molecular functions related to Pilocytic Astrocytoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.88 BRAF ERBB3 FGFR1 GFAP RAF1 SOX10
2 protein kinase activity GO:0004672 9.73 BRAF ERBB3 FGFR1 KDR NTRK2 RAF1
3 kinase activity GO:0016301 9.7 BRAF CDKN2A ERBB3 FGFR1 KDR NTRK2
4 protein tyrosine kinase activity GO:0004713 9.62 ERBB3 FGFR1 KDR NTRK2
5 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.54 ERBB3 FGFR1 PTPN11
6 nucleotide binding GO:0000166 9.43 BRAF ERBB3 FGFR1 HRAS KRAS RAF1
7 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.92 ERBB3 FGFR1 KDR NTRK2

Sources for Pilocytic Astrocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....